Wells Fargo upgraded Doximity (DOCS) to Equal Weight from Underweight with a price target of $62, up from $55. The firm is also raising estimates on product-led growth tailwinds, drug pipeline, and checks pointing to healthy pharma commercial activity. This should translate into positive near-term momentum on earnings, but valuation keeps Wells on the sidelines.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity’s Hold Rating: Navigating Market Momentum and Macroeconomic Uncertainties
- Doximity’s Mixed Market Signals: Positive Growth Amidst Budget Concerns and Rising Competition
- Doximity’s Hold Rating: Balancing Positive Momentum with Legislative Risks and Market Dynamics
- Doximity price target raised to $61 from $52 at Truist
- Doximity upgraded to Outperform from In Line at Evercore ISI